• Login

Alexion Pharmaceuticals

Contact Us Legal Sitemap
  • About Us
  • Soliris in PNH & aHUS
  • R & D
  • Investors
  • Careers
  • News
  • Newsroom Home
  • About Us
  • News Releases
  • By Year
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
  • Financial News
  • Product News
  • Company News
  • Patient Voices
  • Fact Sheets
  • Management Team

Newsroom Search

Advanced Search

Inquiries

Media Contacts

Irving Adler
Exec. Director, Corporate Communications
203-272-2596   
AdlerI@alxn.com

Fact Sheets

  • Alexion Backgrounder
    application/pdf iconAlexion Backgrounder (366.81 KB)
  • Alexion Timeline
    application/pdf iconAlexion Timeline (675.88 KB)
  • Ultra-rare Disease Backgrounder
    application/pdf iconUltra-Rare Disease Backgrounder (1.4 MB)
  • Soliris Fact Sheet
    application/pdf iconSoliris Fact Sheet (87.06 KB)
  • PNH Fact Sheet
    application/pdf iconPNH Fact Sheet (215.69 KB)
  • aHUS Fact Sheet
    application/pdf iconaHUS Fact Sheet (25.33 KB)
  • Complement Backgrounder
    application/pdf iconComplement Backgrounder (44.92 KB)

Please see full Prescribing Information and Important Safety Information for Soliris® (eculizumab).

About Us Soliris & PNH R&D Investors Careers News
Business Wire NewsHQ℠